Harnessing Tumor-Infiltrating Lymphocytes for Improved Cancer Outcomes

Tumor-infiltrating lymphocytes (TILs) form a pivotal part of the immune system’s defense against cancer, and their density, composition, and spatial distribution reflect both tumor biology and the degree of host immune activation. Across multiple carcinoma types—including breast, lung, colorectal, ovarian, and head and neck cancers—recent clinical studies and meta-analyses have shown that high levels of TILs, especially CD8⁺ cytotoxic T cells, are consistently linked with improved prognosis and enhanced responsiveness to chemotherapy and immune checkpoint inhibitors. Standardized assessment tools, such as the Immunoscore in colorectal carcinoma and stromal TIL evaluation guidelines in breast cancer, have improved reproducibility and clinical relevance. TILs not only act as prognostic and predictive biomarkers but are also being harnessed as therapeutic agents in emerging immunotherapy strategies, including adoptive cell therapy. Despite these advances, variability in evaluation methods and the functional heterogeneity of TIL subsets remain challenges. Standardization of assessment protocols and deeper characterization of TIL phenotypes will be essential to fully integrate these immune markers into routine oncology practice and optimize their potential in precision medicine.